Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin

Medical Science Monitor

Volumn 17, Issue 12, 2011, Pages

  Fujino, Tatsuya ^a   Nakamuta, Makoto ^b   Aoyagi, Yoko ^b   Kohjima, Motoyuki ^b   Satoh, Takeaki ^c   Fukuda, Mika ^a   Ishibashi, Hiromi ^a   Yatsuhashi, Hiroshi ^a   Enjoji, Munechika ^b,d  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c Kokura Medical Center   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; HCV; Peg interferon; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

EID: 82755168728     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882127     Document Type: Article

References (39)

1. Alter HJ: HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43: 550-52
2. Aghemo A, Rumi MG, Colombo M: Pegylated IFN-a2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 2009; 7: 925-35
3. Pawlowska M, Pilarczyk M, Halota W: Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16(12): CR616-21
4. Kumada T, Toyoda H, Honda T et al: Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 2006; 49: 112-18
5. Shiffman ML: Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-34
6. Backus LI, Boothroyd DB, Phillips BR, Mole LA: Prediction of response of US veterans to treatment for the hepatitis C virus. Hepatology, 2007; 46: 37-47
7. Kanwal F, Hoang T, Spiegel BM et al: Predictions of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology, 2007; 46: 1741-49
8. Bortoletto G, Scribano L, Realdon S et al: Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat, 2010; 17: 475-80
9. Neumann AU, Lam NP, Dahari H et al: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science, 1998; 282: 103-7
10. Lam NP, Neumann AU, Gretch DR et al: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon a. Hepatology, 1997; 26: 226-31
11. Bekkering FC, Brouwer JT, Leroux-Roels G et al: Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol, 1998; 28: 960-64
12. Zeuzem S, Herrmann E, Lee JH et al: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a. Gastroenterology, 2001; 120: 1438-47
13. Buti M, Sanchez-Avila F, Lurie Y et al: Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon a-2b plus ribavirin. Hepatology, 2002; 35: 930-36
14. Guedj J, Rong L, Dahari H, Perelson AS: A perspective on modeling hepatitis C virus infection. J Viral Hepat, 2010; 17: 825-53
15. Shudo E, Riberio RM, Talal AH, Perelson AS: A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther, 2008; 13: 919-26
16. Shudo E, Riberio RM, Perelson AS: Modeling hepatitis C virus kinetics during treatment with pegylated interferon a-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat, 2008; 15: 357-62
17. Colombatto P, Ciccorossi P, Maina AM et al: Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther, 2008; 84: 212-15
18. Makiyama A, Itoh Y, Yasui K et al: First phase viral kinetic parameters and prediction of response to interferon a-2b/ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res, 2006; 36: 94-99
19. Derbala MF, El Dweik NZ, Al Kaabi SR et al: Viral kinetic of HCV genotype-4 during pegylated interferon a 2a: ribavirin therapy. J Viral Hepat, 2008; 15: 591-99
20. Sasase N, Kim SR, Kudo M et al: Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b. Intervirology, 2010; 53: 49-54
21. Elefsiniotis IS, Vezali E, Mihas C, Saroglou G: Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology, 2009; 52: 247-51
22. McHutchison JG, Lawitz EJ, Shiffman ML et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New Engl J Med, 2009; 361: 580-93
23. McHutchison JG, Sulkowski M: Scientific rationale and study design of the individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat, 2008; 15: 475-81
24. Toyoda H, Kumada T: Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (=2a), that is the question'. Expert Opin Pharmacother, 2009; 10: 2845-57
25. Layden-Almer JE, Cotler SJ, Layden TJ: Viral kinetics in the treatment of chronic hepatitis C. J Hepatol, 2006; 13: 499-504
26. Layden-Almer JE, Layden TJ: Viral kinetics in hepatitis C virus: special patients populations. Semin Liver Dis, 2003; 23(Suppl.1): 29-33
27. Layden-Almer JE, Ribeiro RM, Wiley T et al: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003; 37: 1343-50
28. Nakao R, Yatsuhashi H, Hashimoto S et al: Association between amino acids 70 and 91 in the HCV core region and second-phase viral decline during antiviral therapy for patients with HCV 1b. J Hepatol, 2009; 50; S234
29. Bodenheimer HC Jr, Lindsay KI, Davis GL et al: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997; 26: 473-77
30. Zoulim F, Haem J, Ahmed SS et al: Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat, 1998; 5: 193-98
31. Dusheiko G, Main J, Thomas H et al: Ribavirin treatment for patients with chronic hepatitis C: result of a placebo-controlled study. J Hepatol, 1996; 25: 591-98
32. Pawlotsky JM, Dahari H, Neumann AU et al: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 2004; 126: 703-14
33. Rong L, Perelson AS: Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol, 2010; 30: 131-48
34. Keating G, Curran M: Peginterferon a2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs, 2003; 63: 701-30
35. Luxon BA, Grace M, Brassard D, Bordens R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther, 2002; 24: 1363-83
36. Akuta N, Suzuki F, Kawamura Y et al: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology, 2007; 50: 361-68
37. Suppiah V, Moldovan M, Ahlenstiel G, et al: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 2009; 41: 1100-4
38. Tanaka Y, Nishida N, Sugiyama M et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009; 41: 1105-9
39. Ge D, Fellay J, Thompson AJ et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009; 461: 399-401